HealthCap reposted this
The FDA's Fast Track Designation for CT-0525 is a pivotal milestone for Carisma, reflecting the potential of our therapy to make a significant impact in the treatment of solid tumors.
We are excited to announce that that the U.S. FDA has granted Fast Track Designation for CT-0525, an ex vivo gene-modified autologous CAR-Monocyte cellular therapy intended to treat HER2-overexpressing solid tumors. This marks a significant milestone for Carisma, highlighting the FDA's recognition of the serious and life-threatening nature of these malignancies and the potential of CT-0525 to meet this critical medical need. Read more in the press release here: https://lnkd.in/gqd93wxq #immunotherapy #oncology
Congratulations, Steven, and good news for patients.
Steven Kelly congrats to you and your team!
Congrats Steve, best of luck!
Great news Steve and team!
Congrats, Steve and team!
Congratulations!
Senior Vice President, Northeast Region Executive at Wexford Science & Technology, LLC
4moGreat news for your team and patients, Steve.